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AP-2α and c-MYC are important transcription factors involved in multiple cellular processes. They each display the paradoxical
capacities to stimulate both cell proliferation and apoptosis under diﬀerent conditions. In the present study we found that over
expression of c-MYC was associated with accumulation of reactive oxygen species (ROS) and apoptosis in human keratinocytes,
both of which were signiﬁcantly inhibited by co-expression of AP-2. The eﬀects of AP-2 on c-MYC were active at several levels.
First, AP-2 and c-MYC were conﬁrmed to interact at the protein level as previously described. In addition, forced expression of
AP-2 signiﬁcantly decreased steady state levels of c-MYC mRNA and protein. These ﬁndings suggested that AP-2 may have a direct
eﬀect on the c-myc gene. Chromatin immunoprecipitation assays demonstrated that AP-2 proteins bound to a cluster of AP-2
binding sites located within a 2 kb upstream regulatory region of c-myc These results suggest that the negative regulation of AP-2
on c-MYC activity was achieved through binding of AP-2 protein to the c-myc gene. The eﬀects of AP-2 on c-MYC induced ROS
accumulation and apoptosis in epidermal keratinocytes are likely to play an important role in cell growth, diﬀerentiation and
carcinogenesis of the skin.
Copyright © 2009 Lei Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The c-MYC protein, which is encoded by c-myc gene, is a
nuclear phosphoprotein. This protein belongs to the helix-
loop-helix/leucine zipper (HLH/LZ) family of transcription
factors (including c-MYC, N-MYC, L-MYC, S- and B-
MYC) and recognizes E-box sequences that contain a central
CAC(G/A)TG sequence [1]. Although its precise cellular
functions remain enigmatic, it is clear that c-MYC plays a
critical role at some level in cell proliferation and diﬀeren-
tiation [2]. For example, induction of c-MYC is suﬃcient
to drive quiescent cells into the cell cycle, while inhibition
of c-MYC can block mitogenic signals and facilitate cell
diﬀerentiation [3]. A well-known human disease involving
c-MYC is human Burkitt’s lymphoma [4], in which c-myc
is translocated from chromosome 8 to one of three chro-
mosomes that contain antibody-encoding genes where its
transcriptionisactivatedbythosestronglymphocytespeciﬁc
promoters. Gene ampliﬁcation is another mechanism that
leads to overexpression of c-MYC [5]. More recently, the
overexpression and deregulation of c-myc in many of other
t y p e so ft u m o r sh a v eb e e nd e m o n s t r a t e d[ 6]. Unlike other
proto-oncogene products, c-MYC levels in diﬀerent tumor
types range from lower than their normal cells of origin
to dramatically increased [7]. So deregulation, not simply
ampliﬁcation, is generally considered as the key point of
carcinogenesis caused by c-MYC. Besides promoting cell
proliferation, c-MYC also shows the capacity to induce cell
death [8, 9]. At high levels of expression, c-MYC cannot only
sensitize cells to cell death, but also aﬀect neighboring cells
[10, 11]. The apoptosis induced by c-MYC has been shown
to depend on signaling via FasL/Fas pathway in T cells [12],
increased cellular free radical levels [13], and can be either
p53 dependent or p53 independent [14].2 Journal of Oncology
The exact mechanisms through which c-MYC mediates
its diverse eﬀects on cell fate are unknown. One possibility
is that c-MYC functions as a classical transcription factor in
the formation of heterodimers with Max or Mad and binds
to E box related elements [15]. Another is the interaction of
c-MYC with other proteins which have been predominantly
mapped to occur through its C-terminal region (CTR) and
N-terminal region (NTR). Among the proteins identiﬁed in
a direct interaction with c-MYC, transcription factor AP-2α
(TFAP2A) [2, 16] has been shown to have a similar pattern
of biological behavior as c-MYC.
AP-2 is a transcription factor family that includes ﬁve
members: AP-2α,A P - 2 β,A P - 2 γ,A P - 2 δ, and the recently
identiﬁed AP-2ε. All AP-2 family members share a common
protein structure that includes a DNA binding domain,
a dimerization domain, and a transactivating domain
[17]. These transcription factors regulate the expression of
genes involved in a wide spectrum of important biological
functions, including cell proliferation, diﬀerentiation and
carcinogenesis. AP-2α has previously been shown to interact
with the BR/HLH/LZ domain of c-MYC through C-terminal
domains (amino acids 204–437) of AP-2α and block the
DNAbindingofc-MYC[16].Similartoc-MYC,thefunction
of AP-2α also has been found to be paradoxical. Some
investigators found that AP-2α w a sat u m o rs u p p r e s s o r[ 18,
19] which had the capacity to induce apoptosis, while others
suggested that AP-2α could be a proto-oncogene [20, 21]
which stimulated cell proliferation.
Although it has been shown that AP-2α has a neg-
ative eﬀect on c-MYC transcriptional activity in two
bona ﬁde target genes, prothymosin-alpha and ornithine
decarboxylase [16], it is not clear whether AP-2α has
the capability to inhibit c-MYC induced transformation
or apoptosis. Besides the known protein-protein inter-
action, whether there are other levels of interaction or
regulation between these two transcription factors remains
unknown.
BothAP-2α[22]andc-MY C[23]canbeinducedbyUVA
irradiation. Furthermore, of HaCaT cells exposed to chronic
UVA irradiation showed increased resistance to further UVA
induced apoptosis [24]. Although this study did not measure
the AP-2α levels in those treated HaCaT cells, expression of
the AP-2 target gene MMP9 was found to be signiﬁcantly
higher. We found in our own study that overexpression
of AP-2α in HaCaT cells before UVA irradiation could
signiﬁcantly increase cell survival (Supplemental Figure 1).
These data strongly suggested that increased AP-2α levels
may protect cells from further UVA induced cell death, and
inhibition of UVA-induced c-MYC expression could be one
of the mechanisms behind the protection.
To better understand the biological eﬀects of the inter-
action between c-MYC and AP-2α, we ﬁrst overexpressed
c-MYC and monitored the generation of reactive oxygen
species (ROS) and cell biology parameters including clono-
genic survival and growth rates; then we co-overexpressed
AP-2α to test the hypothesis that AP-2α can block at least
some consequences of c-MYC overexpression in HaCaT
human keratinocytes. AP-2dn, a transactivating domain

















Figure 1: Adenovirus forced overexpression of AP-2 and c-MYC
in HaCaT cells. HaCaT cells were infected with Ad-Bgl II 100MOI
(control), 50MOI Ad-Bgl II + 50MOI Ad-AP-2 (AP-2α), 50MOI
Ad-Bgl II + 50MOI Ad-c-MYC (c-MYC), and 50MOI Ad-AP-
2 + 50MOI Ad-c-MYC (AP-2α + c-MYC). On the c-MYC blot
(middle) the immunoreactivity that corresponds to the forced
overexpression of the c-MYC is shown by the upper band. The
ﬁgure is a representative of at least three independent blots.
cells to test whether the transcriptional activity of AP-2 was
necessary for any eﬀects on c-MYC activity.
2. Results
2.1. Overexpression of c-MYC Increased Intercellular ROS
Levels. Overexpression of c-MYC and AP-2α proteins in
H a C a Tc e l l sw a sc o n ﬁ r m e db yw e s t e r nb l o t( Figure 1).
As early as 9 hours after infection with 50MOI Ad-c-
MYC, the intercellular ROS level, as detected by DCF
method, was signiﬁcantly increased relative to controls
(Figure 2(a)) and by 24 hours it reached to about a 30-
fold increase (Figure 2(b)). Overexpression of AP-2α alone
did not increase ROS level compared to control vector Bgl-
II. Thus, c-MYC overexpression was linked to a signiﬁcant
increase of ROS, while co-overexpression of AP-2α with c-
MYC alleviated the increase of ROS (Figure 2(b)).
2.2. AP-2α Partially Prevented Cell Death Induced by Over-
expression c-MYC in HaCaT Cells. c-MYC overexpression
caused a dramatic decrease of clonogenic cell survival,
with surviving fractions decreasing to approximately 20%
(Figure 3). Coexpression of AP-2α signiﬁcantly rescued the
cells and increased the surviving fraction, doubling it to
approximately 40%. Forced AP-2α overexpression alone did
not have a detectable eﬀect on clonogenic survival in HaCaT
cells at a titer of 50MOI. This is in contrast to results
previouslydeterminedforhumanbreastcarcinomacells[25]
and may reﬂect the relatively higher endogenous level of AP-
2α expression in human keratinocytes.
2.3. AP-2α Attenuated c-MYC Induced Apoptosis in HaCaT
Cells. Two independent assays for apoptosis, propidium
iodide (PI) DNA staining and caspase-3 activation, showed
that overexpression of c-MYC in HaCaT cells induced
apoptosis (Figure 4). Fifty MOI of Ad-c-MYC increased the
sub-G1 apoptotic population about 3 times compared to the
























































Figure 2: c-MYC induced accumulation of ROS in HaCaT cells was
partially reversed by AP-2α. (a) time course showed that as early as
9 hours after infection, ROS level was higher than control (
∗P <
.05 versus control, n = 3); (b) AP-2 reduced the ROS induced by c-
MYC. The intercellular ROS level was measured by DCF method 24
hoursafterinfection. OverexpressionofAP-2alonedidnotincrease
ROS level while co-overexpression AP-2 with c-MYC signiﬁcantly
decreased the accumulation of ROS (
∗P < .05 versus Bg-II and
AP-2;
†P < .05 versus MYC, n = 3).
of AP-2α relieved that increase back to the basal level.
Although sub-G1 content DNA level by PI staining indicates
death, it is not speciﬁc for apoptosis. Thus, the activated
caspase-3 assay was employed as it is more speciﬁc to
the detection of apoptosis in these cells (Figure 4(b)). c-
MYC increased the fraction of the active caspase-3 positive
populationfrom4.5%to40%(∼10fold),whilecoexpression
of AP-2α decreased this increase to around 15% (∼3f o l d )
(Figure 4(b)).
2.4. AP-2α Inhibits the Expression of Endogenous c-myc. After
we found that overexpression of AP-2 could inhibit at
least some of the consequences of exogenously expressed
c-MYC, we further investigated whether AP-2 had similar
eﬀects on endogenous c-MYC. AP-2α and c-MYC are both
transcription factors; therefore, besides the direct protein
interaction, it is possible that these two factors aﬀect each
others’geneexpression.WefoundthatoverexpressionofAP-




















Control AP-2α c-MYC AP-2α + c-MYC
P = .0006
Figure 3: c-MYC induced cell death in HaCaT cells was partially
reversed by AP-2α. Twenty-four hours after infection, 100 cells
from each group were seeded and cultured under normal growth
conditions for 10–14 days. Colonies with ≥ 50 cells were counted.
AP-2α increased clonogenic survival in c-MYC overexpressing
HaCaTcells.Thesurvivingfractionswerecalculatedbynormalizing
the number of colony of each treated group to that of the control
group, respectively. Error bars stand for standard deviations, n = 3.
and protein compared to the vector control (Figures 5(a)
and 5(b)). Interestingly, a transactivation domain deletion
mutant of AP-2α had a similar eﬀect, suggesting that there
is a blocking eﬀect of AP-2 on the c-MYC promoter.
Analysis of 2kb 5  ﬂanking region of the c-myc gene
revealed that there were 11 putative AP-2 binding sites
located within that area and three more in the ﬁrst intron
(Figure 6(a)). To determine whetherAP-2is capableofdirect
DNA binding to these cis elements, we performed in vivo
quantitative chromatin immunoprecipitate (qChIP) assays.
The qChIP assays showed that overexpression of AP-2α
caused signiﬁcant enrichment (approximately 6 folds) for
both selected promoter regions analyzed compared to the
vector control group (Figure 6(b)). Another genomic region
that was previously known to contain an AP-2 binding site,
the ICAM-1 promoter [22], was used as a positive control,
and was enriched approximately 10 folds (data not shown).
Sincetheinteractionbetweenthesetwoproteinsrequiredthe
C-terminal end of both proteins [16]a n db l o c k e dc - M Y C
DNAbinding,wetestedwhetherthisinteractionalsoblocked
AP-2 DNA binding. We found, in vitro, that an increase
of c-MYC protein amount caused a decrease of AP-2 DNA
bindingwhichwasdetectedbygelshiftassay(Supplementary
Figure 2 in supplementary material available online at doi
10.1155/2003/780874) and, in vivo, cooverexpression of c-
MYC could decrease the binding of AP-2 to c-myc promoter
(Figure 6(b)).
3. Discussion
The Myc family of nuclear oncoproteins, including c-MYC,
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Figure 4: Wild type AP-2α attenuated apoptosis induced by c-MYC in HaCaT cells. HaCaT cells were infected with Ad-Bgl II 100MOI
(Control), 50MOI Ad-Bgl II + 50MOI Ad-AP-2 (AP-2α), 50MOI Ad-Bgl II + 50MOI Ad-c-MYC (c-MYC), or 50MOI Ad-AP-2 + 50MOI
Ad-c-MYC (AP-2α + c-MYC). Propidium iodide (PI) staining for sub-G1 and phycoerythrin (PE)-conjugated anti-caspase-3 antibody
staining for active caspase-3 were performed as indicated in the Materials and Methods section. (a) AP-2α decreased the sub-G1 population
induced by c-MYC. Upper panels: representative ﬂow cytometry plots of PI-sub-G1 DNA content (M1) in the variously treated cells.
Lower panel: quantitative determination of sub-G1 DNA content. Error bars represent standard deviations, n ≥ 4.
∗P < .01 compared
to control, AP-2α, and AP-2α + c-MYC groups. (b) AP-2α decreased the percentage of cells positive for active caspase-3 induced by c-MYC.
Upper panels: representative ﬂow cytometry plots of measurement of PE-active caspase-3. Lower panel: quantitative determination of active
caspase-3. Error bars represent standard deviations, n ≥ 4.
∗P < .01 compared to control,
†P < .05 compared to control and c-MYC group.
them, c-MYC has attracted a great deal of attention because
of its broad relationship to human oncogenesis. c-MYC
is overexpressed in many cancer types while at the same
time, it also exhibits the ability to induce apoptosis [6, 9].
The mechanisms through which c-MYC mediates its diverse
eﬀects are unknown. Besides functioning as a traditional
transcription factor binding to DNA elements, c-MYC has
been also found to directly interact with a diverse array of
other proteins including p107, BIN1, TRRAP, MM-1, AMY-
1,Pam,α-tubulin,Max,YY1,AP-2,TFII-I,BRCA1,andMiz-
1[ 2]. The C-terminal domain (CTD) of c-MYC interacts
with Max to form heterodimers and binds to DNA elements,
while the N-terminal domain shows both transcription
activation and transcription repression functions. Gaubatz
et al. showed that AP-2α interacted with the c-MYC CTD
both directly and indirectly [16]. These authors showed
that AP-2α inhibited c-MYC DNA binding activity at the
ornithine decarboxylase promoter either by competing with
Myc/Max heterodimers for the E-box at the promoter region
or by interacting with c-MYC directly within its CTD.
In the present study we found that overexpression of





































Figure 5: Both wild type and dominant negative AP-2 inhibit
endogenous c-myc expression. HaCaT cells were infected with Ad-
Bgl II (Control), wild type AP-2α, dominant negative AP-2, or
c-MYC adenovirus at 100MOI. Twenty-four hours later, nuclear
protein and total RNA were extracted. (a) c-MYC mRNA level
decreased to about 50% compared to control group after AP-
2 infection (
∗P < .05 versus BglII control, n = 3). (b) c-MYC
protein level decreased after AP-2 infection, The fourth lane is
a positive control sample from Ad-c-MYC infected HaCaT cells
(representative blot of three independent experiments).
and signiﬁcantly decreased clonogenic survival, and that this
was associated with signiﬁcantly increased ROS levels. Since
AP-2α has been shown to inhibit c-MYC activity possibly
through a protein-protein interaction [16], we hypothesized
that AP-2α attenuated apoptosis induced by c-MYC through
this mechanism; and since the protein-protein interaction
is via the C-terminus of AP-2α, we also hypothesized that
the transactivating domain of AP-2α was not required for
suchinhibition.Ourcurrentﬁndings,thatco-overexpression
of AP-2α resulted in decreased ROS levels, increased sur-
vival, and decreased apoptosis induced by c-MYC provide
support for these hypotheses. More importantly, our study
demonstrates for the ﬁrst time that AP-2α directly bound to
the c-myc 5  ﬂanking regulatory region in vivo and blocked
the expression of c-MYC mRNA (Figures 5 and 6). There
are 11 putative AP-2 binding sites located within the 2kb
5  ﬂanking region of the c-myc gene. We chose two clusters
of these sites close to the transcription start site for ChIP
analysis. We found that when AP-2 (either wild type or
dominant negative) was overexpressed, c-MYC expression
was inhibited and at the same time, the binding of AP-2
to those two clusters increased approximately by 6 folds.
Analysis of the c-myc promoter sequence also revealed other
transcription factor binding sites overlapping the AP-2 sites.
These transcription factors include Sp1, NF-1, GATA-1, and
GR.SinceSp1mediatedtheactivationofc-myc [26]aswellas
many other genes, the overlapping AP-2 binding sites suggest
a mechanism for c-MYC inhibition similar to that by which
AP-2α inhibits the expression of MnSOD by competing with
Sp1 on the MnSOD promoter [21].
Both c-MYC and AP-2α proteins have paradoxical eﬀects
in carcinogenesis and apoptosis. In our study we found
that at 50MOI, Ad-c-MYC could cause a massive apoptosis
in HaCaT cells. HaCaT cells express mutant p53 [27, 28],
thus we believe that the apoptosis induced by c-MYC in
our study was p53 independent. AP-2α has been shown to
directly interact with p53 [29]a n dm a yt h u sh e l pr e g a i nt h e
DNAbindingandtranscriptionalactivityofmutantp53.The
inhibition of the apoptosis executed by AP-2α in our study
seems to occur through a direct block to c-MYC protein and
was p53 independent.
In summary, as a negative regulator for c-MYC, AP-2α
inhibits c-MYC at two diﬀerent levels. First, AP-2α directly
inhibits c-myc gene expression through binding to its 5 
regulatory region. Second, AP-2α has the ability to attenuate
the apoptosis induced by c-MYC through protein-protein
interaction and this eﬀect did not require the transcriptional
activity of AP-2.
4.MaterialsandMethods
4.1. Adenovirus Construction. The AP-2dn cDNA (a mutant
form of AP-2α with a deletion of the transactivation domain
encompassing amino acids 31–117) was provided by Dr.
Lubomir Turek and was subcloned into pcDNA3 [30]. The
coding sequences were then cloned into a shuttle vector
provided by Gene Transfer Vector Core, the University
of Iowa. The E1A replication deﬁcient adenovirus was
constructedwiththeestablishedprotocol[31].Thewildtype
AP-2α [30] adenovirus was constructed with same method
and has been previously described [25]. The Ad-c-MYC [32]
was ampliﬁed and maintained by the Gene Transfer Vector
Core at The University of Iowa.
4.2. Cell Culture. HaCaT cells [33] were cultured in Dul-
becco’s Modiﬁed Eagle Medium (DMEM) supplemented
with 10% FBS at 37
◦C in a humidiﬁed atmosphere of
5% CO2 and 95% air to reach 70–90% conﬂuence prior
to adenovirus infections. For clonogenic survival analyses,
cells were infected with Ad-Bgl II, Ad-AP-2α, Ad-c-MYC, or
Ad-AP-2dn as indicated. Twenty-four hours later, cells were
trypsinizedandcounted.Onehundredcellsfromeachgroup
were seeded into each well of six-well plates. After 14 days
under normal growth condition, the resulting colonies were
stained with 0.5% crystal violet in 70% ethanol, and colonies
with ≥ 50 cells were counted under dissection microscope.
For growth curve, cells in sample wells were counted every
other day.
4.3. Intracellular Peroxide Measurement. The intracellu-
lar peroxide concentration was measured with 2 ,7 -
dichlorodihydroﬂuorescein diacetate (DCFH-DA) as previ-
ously described [34]. Brieﬂy, cells were washed with 1 × PBS,
and 3mL of 10μM DCFH-DA (20μLo f2 0 m Ms t o c ki n6 Journal of Oncology
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Figure 6: AP-2α protein bound to c-myc 5  ﬂank regulatory region. (a) Diagram of the location of AP-2 putative binding sites in c-myc
5  ﬂank regulatory region (short columns). The gray short arrow heads represent the primers for ChIP assay. (b) Overexpression of AP-2α
caused enrichment of two promoter regions DNA with anti-AP-2 antibody in ChIP assay. Region I (−403 to −277) and Region II (−250
to −11) were both enriched about 6 folds. Cooverexpression of c-MYC (50MOI) decreased AP-2 binding to c-myc promoter back to basal
level. Upper panels are representative ampliﬁcation curves of the real time PCR for ChIP assay; lower panel is a plot of the quantiﬁcation of
the data calculated with ΔΔCt. Error bars stand for standard deviation (SD), n = 3.
∗P < .05 compared to control.Journal of Oncology 7
40mL PBS, Molecular Probes) was added to each plate and
incubated at 37
◦C for 30 minutes. Cells were washed with
PBS, and then lysed with 800μL of 0.5% NP-40. Cell lysates
were centrifuged at 10000×ga t4 ◦C for 3 minutes. 180μLo f
lysatefromeachsamplewasloadedinto96-wellNUNCblack
bottomplateandreadinaSPECTRAFLUORPlusmicroplate
reader (TECAN, Austria) with excitation wavelength of
485nm and emission wavelength of 530nm. The protein
concentration in the remaining lysate was determined and
DCF ﬂuorescence intensity per mg protein was calculated. In
separate control groups, an oxidized (DCF-DA) probe was
used the same way to control for the uptake and eﬄux of the
probe.
4.4. Apoptosis Assay. Two methods were applied to analyze
the fraction of apoptotic cells. For propidium iodide (PI)
staining, 1 × 106 cells from each group were ﬁxed with 70%
ethanol at 4◦C for one hour. Cells were then washed two
times with 1 × PBS and then stained with 50μg/mL PI at the
presence of 0.25mg/mL RNase A at 4◦Cf o r3 0m i n u t e sa t
dark. The Active Caspase-3 Apoptosis Kit (BD Pharmingen,
catalog number 550914) was used for the active caspase-3
analysis according to the manufacturer’s instructions. The
number of cells in the sub-G1 population was obtained by
counting 10000 cells for each sample by ﬂow cytometry
(Becton Dickinson FACscan). For active capase-3, 30000
c e l l sw e r ec o u n t e df o re a c hs a m p l e .
4.5. Nuclear Protein Extraction. After treatment, cells were
harvested by trypsinization and collected by centrifuga-
tion in 15mL tubes. Cell pellets from individual cultures
were rinsed twice in ice-cold PBS and resuspended in
0.5mL of ice-cold hypotonic buﬀer [20mM HEPES-HCl
(pH 7.6), 1mM ethylenediamine tetraacetic acid (EDTA),
10mM NaCl, 1mM dithiothreitol, and 0.5% Nonidet P-
40] containing protease inhibitors. The cell suspension was
transferred to a 1.5 mL microfuge tube, incubated on ice
for 20 minutes, vortexed for 10 seconds, and centrifuged for
60 seconds at 6000g. The supernatant (cytoplasmic extract)
was transferred to a new tube. The pelleted nuclei were
washed twice with 1mL of ice-cold hypotonic buﬀer and
resuspended in 0.1mL of extraction buﬀer (20mM HEPES-
HCl pH 7.6, 1mM EDTA, 430mM NaCl, 1mM dithio-
threitol, and 0.5% Nonidet P-40) containing the protease
inhibitors. After 20 minutes on ice with occasional shaking,
the suspension was centrifuged for 15 minutes at 16000g at
4◦C, and the supernatant (nuclear extract) was transferred
to a new tube. After determination of protein concentra-
tion, aliquots of each extract were stored at −80
◦C until
use.
4.6. Western Blot Assay. Proteins were boiled with same
volume of 2 × sample buﬀer (125mM Tris pH 6.8, 4%
SDS, 10% glycerol, 0.006% bromophenol blue, and 1.8%
beta-mercaptoethanol) and were separated in a 12% SDS-
PAGE gel, then transferred to nitrocellulose membranes at
100V, 4◦C for 1 hour. The membrane was blocked with 5%
nonfat milk at room temperature for 1 hour and incubated
with either AP-2α antibody 3B5 (Santa Cruz Biotechnology,
SantaCruz,CA)orMYCantibody(obtainedfromUniversity
of Iowa Hybridoma Core) 1 : 1000 at room temperature
f o r1h o u r .T h em e m b r a n ew a sw a s h e dw i t h1× TBST
(10mM Tris-HCl, pH 7.5, 150mM NaCl, 0.05% Tween-
20) buﬀer 5 times for 5 minutes each and then incubated
with the second antibody (goat anti-mouse, HRP labeled, 1 :
10000) at room temperate for 45 minutes. The membrane
was washed again with 1 × TBST buﬀer 5 times for 5
minutes each time and the proteins were visualized by
adding ECL buﬀer to the membrane and exposing to X-ray
ﬁlm.
4.7. RNA Extraction, Reverse Transcription, and Quantitative
PCR for Measuring c-MYC mRNA. RNeasy Kits (Qiagen)
were used to extract total RNA following manufacturer’s
protocol.High Capacity cDNAArchive kits fromABI(Foster
City, CA) were used to prepare cDNA following manu-
facturer’s protocols. Brieﬂy, 2μg of total RNA was reverse
transcribedtocDNAina100μLr eactionat37
◦Cfor2hours.
Every 1μL RT reaction is equivalent to cDNA resulting from
20ng RNA. Steady state c-MYC mRNA levels were measured
usingtheSYBRGreenmethod(ABI,Valencia,CA)according
to manufacturer’s instructions. The primers for c-MYC were
forward: 5 -CCA CAC ATC AGC ACA ACT ACG CT and
reverse: 5 -GCA TTT TCG GTT GTT GCT GAT C. The
primers for 18S were forward: 5 -ACC GCG GTT CTA TTT
TGT TG and reverse: 5 -CCC TCT TAA TCA TGG CCT
CA. The relative c-MYC mRNA levels were calculated by
normalizing to 18 seconds and comparing the ΔΔCt between
control group and AP-2 overexpressed group according to
manufacturer’s instructions.
4.8. In Vivo Quantitative Chromatin Immunoprecipitation
(qChIP) Assay. Twenty million HaCaT cells from each
group were cross-linked for 15 minutes at 37
◦C using 1%
formaldehyde. Cells were washed twice with 1 × PBS.
The cells were then pelleted by centrifugation at 500g for
10 minutes and resuspended in 500mL sonication buﬀer
(50mM Tris-Cl pH 8.1, 10mM EDTA, and 1% SDS +
protease inhibitors) and sonicated twice for 10 seconds to
achieve an optimal fragment length between 300–600bp.
Cross-linked DNA/proteins were then diluted 1 : 10 using
IP dilution buﬀer (0.01% SDS, 1.1% Trition-X 100, 1.2mM
EDTA, 16.7mM Tris-Cl, pH 8.1, 167mM NaCl) plus pro-
tease inhibitors. Samples were then precleared using 70μL
of Protein G agarose (Upstate Biotech, Charlottesville, VA)
for 1 hour at 4◦C. Approximately 1/10th of the sample was
removedasinputcontrol,whiletheremainderwasimmuno-
precipitated with 10μg of anti-AP-2α (Upstate Biotech,
Charlottesville, VA) or control mouse IgG overnight at 4◦C
with agitation. Chromatin/antibody complexes were then
collected using Protein G agarose followed by washing and
elutionaccordingtothemanufacturer’sprocedure.DNAwas
puriﬁed from input chromatin and immunoprecipitation
elutions by reversing cross-links using 200mM NaCl at 65
◦C
for 4 hours followed by the Qiagen DNeasy Kit (Qiagen,
Valencia, CA) according to manufacturer’s protocol. Puriﬁed8 Journal of Oncology
DNA was then quantiﬁed by using a Biophotometer (Eppen-
dorf, Hamburg, Germany). Five ng of DNA from input, anti-
AP-2 pull down, and nonspeciﬁc antibody pull down were
analyzed with real time PCR from each of the following
groups: total input, anti-AP-2 IP, and nonspeciﬁc antibody
IP.
The primer sequences for amplifying the c-myc promoter
r e g i o nIw e r ef o r w a r d :5  -TCC ATG CGG CTC TCT TAC
TCT G and reverse: 5 -GCT TTG GGA ACC CGG G. For
the second region they were forward: 5 -ATC CTC TCT
CGC TAA TCT CCG C and reverse: 5 -AAT TAC TAC AGC
GAG TTA GAT AAA GC. We used a previously known AP-2
binding site in ICAM-1 promoter [22] as a positive control.
The primer sequences for the ICAM-1 promoter region:
forward: 5 -AGG ATG ACC CTC TCG GCC and reverse: 5 -
TGC TGC AGT TAT TTC CGG ACT. The fold-enrichments
werecalculatedbycomparingtheΔΔCt[35]betweenc ontr ol
group and AP-2 overexpressed group. ΔCt = Ct (Anti-AP-2
pull down) − Ct(Nonspeciﬁc Ab pull down). ΔΔCt = ΔCt
(AP-2 overexpressed group) −ΔCt (Control group). Fold of
enrichment = 2−ΔΔCt.
4.9. Statistical Analysis. A single factor ANOVA, followed by
Student’s t-test was used to compare statistical diﬀerences
between means. Statistical signiﬁcance was set at the 0.05
level.
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